Related Experiment Videos

Biochemical markers in heart failure

Yukihito Sato1, Hisayoshi Fujiwara, Yoshiki Takatsu

  • 1Department of Cardiology, Hyogo Prefectural Amagasaki Hospital, Higashidaimotsucho 1-1-1, Amagasaki, Hyogo, Japan. yukihito.sato@gmail.com

Journal of Cardiology
|December 6, 2011
PubMed

Insights

Diagnosing heart failure (HF) is difficult due to vague symptoms. This review explores biochemical markers for early HF diagnosis, risk assessment, and monitoring treatment effectiveness.

Area of Science:

  • Cardiology
  • Biochemistry
  • Clinical Medicine

Background:

  • Chronic heart failure (HF) is a significant cause of mortality in industrialized nations.
  • Early diagnosis and management of HF are often hindered by nonspecific clinical signs.
  • Biochemical markers are increasingly important for understanding and managing HF.

Purpose of the Study:

  • To review the current knowledge on biochemical markers for heart failure.
  • To highlight the criteria for an ideal HF biochemical marker.
  • To discuss the role of these markers in diagnosis, prognosis, and treatment response.

Main Methods:

  • Literature review of existing studies on heart failure biomarkers.
  • Analysis of the properties and applications of various biochemical markers.
  • Synthesis of current understanding regarding HF biochemical markers.

Main Results:

  • Biochemical markers are crucial for overcoming diagnostic challenges in heart failure.
  • An ideal marker should aid in early diagnosis, risk stratification, and assessing therapeutic response.
  • Current research focuses on identifying and validating specific biomarkers for HF.

Conclusions:

  • Biochemical markers offer a promising avenue for improving heart failure management.
  • Further research is needed to fully utilize the potential of these markers in clinical practice.
  • Effective biomarkers can lead to better patient outcomes and risk assessment in heart failure.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...